Clinical trial NCT01744249: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Official title: A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Neuroendocrine Tumors
Advanced Cancer
Keywords: Advanced neuroendocrine tumours of non-pancreatic origin
axitinib
Lead sponsor: Grupo Espanol de Tumores Neuroendocrinos
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2012-12-06
Enrollment: 255
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Assess whether therapy with axitinib, a potent angiogenic inhibitor of the tyrosine kinase receptors of VEGF bioavailable by oral administration, is capable of improving PFS in patients with advanced G1-G2 NETs of nonpancreatic origin with progressive disease documented in the 12 months prior to entering the study.

Detailed description: Phase II/III, prospective, multicenter, randomized (1:1), double-blind study to evaluate the efficacy and tolerability of axitinib in patients diagnosed with advanced G1-G2 neuroendocrine tumors (WHO 2010) of nonpancreatic origin that have presented documented disease progression in the 12 months prior to entering the study. In the first part of the study (Phase II), 105 patients were enrolled. The second part of the study is the expansion to Phase III, which is expected to include 148 additional patients. Patients will be randomized to receive Sandostatin LAR with axitinib or Sandostatin LAR with placebo until disease progression or unacceptable toxicity occurs. Randomization will be stratified by the time from diagnosis to enrollment in the study (more vs less than or equal to 12 months), the origin of the primary tumor (gastrointestinal tract vs non-gastrointestinal tract \[lung or other sites\]) and ki-67 (\< 5% vs \> 5%).

Eligibility criteria: Inclusion Criteria:

1. G1-G2 neuroendocrine tumor (WHO 2010) of histologically confirmed non-pancreatic origin, functioning and nonfunctioning
2. Metastatic or locally advanced disease not amenable to treatment with curative intent
3. Clinical and/or radiological disease progression documented in the 12 months prior to study entry.
4. Patients should have at least one measurable lesion as defined by RECIST 1.1 criteria. Patients should not have undergone local or regional ablative procedures (embolization, cryoablation, radiofrequency ablation, or others) in the 6 months prior to entering the study, unless there are other locations of measurable disease or clear radiological progression after carrying out these procedures (in these cases, local and regional ablation procedures shall be permitted if they have been performed at least 1 month prior to enrollment in the study).
5. Ki-67 \< 20%
6. Prior treatment with somatostatin analogues is allowed
7. Prior treatment with interferon is allowed
8. Prior treatment is allowed with up to 2 antineoplastic systemic treatment lines different from SAs or IFN (systemic treatment is understood as conventional cytotoxic chemotherapy or new drugs for therapeutic targets as mTOR or other, as long as it is not directed against VEGF/VEGFR). Treatment with SAs or IFN does not count as prior lines of antineoplastic treatment.
9. Prior treatment with targeted therapy against VEGF or VEGFR is not allowed.
10. Adequate organ function as defined by the following criteria:

    * Absolute neutrophil count ≥ 1500 cells/mm3,
    * Platelet count ≥ 75,000 cells/mm3,
    * Hemoglobin ≥ 9.0 g/dL,
    * AST y ALT ≤ 2.5 x upper limit of normal (ULN), except if liver metastases exist, in which case AST and ALT 5.0 ≤ x ULN is allowed,
    * Total bilirubin ≤ 1.5 x ULN,
    * Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min,
    * Proteinuria \< 2+ by reactive strip. If the reactive strip is ≥ 2+, a 24-hour urine sample should be collected and the patient may be eligible if urinary protein excretion is \< 2 g every 24 hours.
11. Men or women aged ≥ 18 years.
12. ECOG performance status 0-2
13. Life expectancy ≥ 12 weeks
14. At least 4 weeks should pass from the end of the previous systemic treatment with resolution of all treatment-related toxicities to grade ≤ 1 according to NCI CTCAE Version 4.0 or to baseline, except for alopecia or properly treated hypothyroidism.
15. No prior evidence of uncontrolled hypertension should exist, as documented by 2 baseline blood pressure readings taken at least 1 hour apart. Baseline readings of systolic blood pressure should be ≤ 150 mm Hg and baseline readings of diastolic pressure should be ≤ 90 mm Hg. Patients whose hypertension is being controlled with antihypertensive therapy are eligible.
16. Women (or their partners) should be surgically sterilized or postmenopausal, or must agree to use an effective contraceptive method during and for at least 6 months after receiving study treatment. All women of childbearing age should have a negative pregnancy test (serum/urine) within 7 days prior to starting treatment. Men (or their partners) should be surgically sterilized or must agree to use an effective contraceptive method during and for at least 6 months after receiving study treatment. The definition of an effective contraceptive method must comply with local regulations and will be based on the criterion of the principal investigator or a designated associate. Lactating women may not participate in this study.
17. Signed and dated informed consent document stating that the patient has been informed of all the pertinent aspects of the trial prior to recruitment.
18. Willingness and ability to comply with scheduled visits, treatment plans (including willingness to take axitinib or placebo according to randomization), laboratory tests, and other study procedures.

Exclusion Criteria:

1. Subjects must be evaluated with regard to the following exclusion criteria:

1. The following types of endocrine tumors will not be included: paraganglioma, adrenal endocrine tumor, thyroid, parathyroid, or pituitary.
2. Major surgery within previous 4 weeks, or radiation therapy within 2 weeks prior to the start of treatment. Prior palliative radiotherapy for metastatic lesions is permitted if there is at least one measurable lesion that has not been irradiated (i.e., if there are other non-irradiated target lesions).
3. Gastrointestinal abnormalities, including:

   * Inability to swallow oral medication;
   * Need for intravenous feeding;
   * Prior surgical procedures that affect absorption, including total gastric resection;
   * Treatment for active peptic ulcer in the last 6 months;
   * Uncontrolled active gastrointestinal bleeding unrelated to cancer, as evidenced by hematemesis, hematochezia or clinically significant melena in the last 3 months without evidence of resolution documented by endoscopy or colonoscopy;
   * Malabsorption syndromes;
4. Current or anticipated need for treatment with drugs that are potent inhibitors of CYP3A4 (grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, and delavirdine) unless they can be replaced by another medication with minimal potential for CYP3A4/5 inhibition. The use of low-dose oral steroids (\< 5 mg/day prednisone or equivalent) is allowed. Co-administration of steroids may increase plasma concentrations of axitinib.
5. Current use or anticipated need for treatment with drugs that are known potent CYP3A4/5 inducers (carbamazepine, dexamethasone, felbamate, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampicin, and St. John's wort) unless they can be replaced by another medication with minimal potential for CYP3A4 induction. Co-administration of CYP3A4/5 inducers may decrease plasma concentrations of axitinib.
6. Need for anticoagulant therapy with oral vitamin K antagonists. Low doses of anticoagulants to maintain the patency of a central venous access device or to prevent deep vein thrombosis are permitted. Use with therapeutic doses of low molecular weight heparin is allowed.
7. Clinically relevant history of bleeding in the last 6 months, including severe hemoptysis or hematuria, unless it has been due to a treated cause (e.g., completely resected bleeding intestinal tumor).
8. Active epilepsy or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis.
9. Serious uncontrolled illness or active infections that may interfere with the patient's ability to receive the study treatment.
10. Any of the following events in the 12 months prior to administration of the study drug: myocardial infarction, uncontrolled angina, implantation of a coronary or peripheral bypass, symptomatic congestive heart failure, stroke or transient ischemic attack. Deep vein thrombosis or pulmonary embolism in the prior 6 months.
11. Ongoing grade ≥ 2 cardiac arrhythmias according to NCI CTCAE: atrial fibrillation of any grade or QTc interval \> 450 ms for men or \> 470 ms for women.
12. Patients with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome-related disease.
13. Prior history of cancer except those treated with curative intent for non-melanoma skin cancer in situ, breast or cervical cancer in situ, or those treated for any cancer with curative intent and no evidence of disease in the last 5 years prior to enrollment in the study.
14. Dementia or significantly altered mental status that could prevent compression, or submission of informed consent and compliance with the requirements of this protocol.
15. Any severe, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with participation in the study or with study drug administration, or that may interfere with the interpretation of results, and that could interfere with the patient's ability to take part in this study in the investigator's opinion.
16. The patient's participation or intention to participate (in the 4 weeks prior to starting drug administration) in a study in which the patient will receive an investigational medicinal product.
17. Subjects who are institutionalized by governmental or by judicial decision, or subjects who are dependent of the sponsor, the investigator or the trial site will be excluded from participation.

Primary outcomes:
measure: Effectiveness of axitinib in terms of PFS
timeFrame: until disease progression, end of treatment or minimum 6 months
Secondary outcomes:
measure: Objective response rate (ORR) and the duration of response.
timeFrame: Until disease progression, end of treatment or minimum 6 months
measure: Functional response rate using F-DOPA-PET (optional, depending on availability)
timeFrame: Until disease progression, end of treatment or minimum 6 months
measure: Biochemical response (5-OH-indoleacetic acid and chromogranin A)
timeFrame: Until death, last follow-up, or minimum 6 months
measure: Safety and tolerability of axitinib (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE], version 4.0)
timeFrame: Until disease progression, end of treatment or minimum 6 months
measure: Explore potential biomarkers
timeFrame: Until disease progression or or minimum 6 months
measure: Evaluate overall survival.
timeFrame: from the date of randomization to the date of death from any cause whichever came first, assessed up to 50 months.
Other outcomes:
Locations:
city: Marburg
country: Germany
facility: Marburg Universitätsklinikum Giessen und Marburg GmbH
city: Perugia
country: Italy
facility: Azienda Ospedaliera Universitaria di Perugia
city: Rome
country: Italy
facility: Sapienza, Universitá di Roma, Ospedale sant'Andrea
city: Oviedo
country: Spain
facility: Hospital Central de Asturias
state: Asturias
city: L'Hospitalet de Llobregat
country: Spain
facility: Institut Català d'Oncologia L'Hospitalet
state: Barcelona
city: Málaga
country: Spain
facility: Hospital Universitario Virgen de la Victoria
state: Malaga
city: Vigo
country: Spain
facility: Hospital Alvaro Cunqueiro
state: Pontevedra
city: A Coruña
country: Spain
facility: Complejo Hospitalario Univ A Coruña
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron
city: Burgos
country: Spain
facility: Hospital Universitario de Burgos
city: Granada
country: Spain
facility: Hospital Virgen de las Nieves
city: Leon
country: Spain
facility: Hospital universitario de Leon
city: Madrid
country: Spain
facility: MD Anderson Cancer Center
city: Madrid
country: Spain
facility: Hospital Clara Campal
city: Madrid
country: Spain
facility: Hospital Clínico San Carlos
city: Madrid
country: Spain
facility: Hospital Gregorio Marañón
city: Madrid
country: Spain
facility: Hospital Univ La Paz
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
city: Salamanca
country: Spain
facility: Hospital Univ de Salamanca
city: San Sebastian
country: Spain
facility: Hospital de Donostia
city: Santander
country: Spain
facility: Hospital Marqués de Valdecilla
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen del Rocío
city: Valencia
country: Spain
facility: Hospital General Universitario de Valencia
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet
city: Bebington
country: United Kingdom
facility: Clatterbridge Cancer Centre
state: Wirral
Study officials:
affiliation: Hospital 12 de Octubre
name: Rocio Garcia Carbonero, MD
role: STUDY_CHAIR
References:
citation: Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.